EUVIMEDDescobrir EUVIMED
Crossref

Post‐transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia

Anastasya Svyatoslavovna Borovkova iD, Olesya Vladimirovna Paina iD, Elena Vladimirovna Semenova iD, Tatiana Alexandrovna Bykova iD, Anna Alekseevna Osipova iD, Olga Alexandrovna Slesarchuk iD, Polina Valerievna Kozhokar iD, Lubov Alexandrovna Tsvetkova iD, Zhemal Zarifovna Rakhmanova iD, Andrei Vadimovich Kozlov iD, Alexei Borisovich Chukhlovin iD, Ilya Viktorovich Kazantsev iD and 6 more

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15181 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Anastasya Svyatoslavovna Borovkova and 17 co-authors. Institution: RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Graft vs Host Disease. Cited 1 times so far (Crossref); 38 references.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Introduction

The data on post‐transplant cyclophosphamide (PTCy) in pediatric acute leukemia after matched allo‐HSCT are limited to case series. The present study aimed to assess the results of PTCy‐based GVHD prophylaxis in a large cohort of children with acute leukemia after matched allo‐HSCT.

Methods

A retrospective analysis of 190 pediatric patients with acute leukemia who had a first allograft between 2008 and 2020 from a matched sibling donor (MSD) or matched unrelated donor (MUD) was carried out. In the MSD setting, GVHD prophylaxis consisted of PTCy alone ( n = 28) for the study group, and calcineurin inhibitor (CNI) ± antimetabolite ( n = 30) for the control group. In MUD setting, most patients in the study group received GVHD prophylaxis with PTCy+CNI+mycophenolate mofetil ( n = 42, 66.7%) or PTCy+CNI+sirolimus ( n = 12, 19%). All patients ( n = 69) in the control group received ATG+CNI+antimetabolite.

Results

After MUD allo‐HSCT, the incidences of acute GVHD grade III‐IV and moderate/severe chronic GVHD were significantly lower in the PTCy group compared to control (6.6% vs. 35.0% and 12.7% vs. 47.1%, respectively, p < .0001). Five‐year GVHD‐free, relapse‐free survival (GRFS) after MUD allo‐HSCT was higher in the PTCy group compared to control (35.1% vs. 7.3%, p < .0001). At the same time, there was no significant difference between both groups after MSD allo‐HSCT.

Conclusions

In pediatric acute leukemia, PTCy‐based GVHD prophylaxis for MUD allo‐HSCT is a feasible and effective option that results in a low incidence of GVHD. Compared to the ATG‐based approach, PTCy provides better control of GVHD in children. In pediatric allo‐HSCT from MSD, PTCy demonstrates comparable effectiveness to conventional GVHD prophylaxis.

Subjects

MeSH terms (MEDLINE)

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteGraft vs Host DiseaseHumansChildRetrospective StudiesCyclophosphamideImmunosuppressive AgentsMycophenolic AcidAcute DiseaseCalcineurin InhibitorsAntimetabolitesUnrelated Donors

Author keywords

childrenleukemiamatched donorpost-transplant cyclophosphamide

Substances

CyclophosphamideImmunosuppressive AgentsMycophenolic AcidCalcineurin InhibitorsAntimetabolites

Authors and institutions

  • RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation.

ORCID profiles: Anastasya Svyatoslavovna Borovkova, Olesya Vladimirovna Paina, Elena Vladimirovna Semenova, Tatiana Alexandrovna Bykova, Anna Alekseevna Osipova, Olga Alexandrovna Slesarchuk, Polina Valerievna Kozhokar, Lubov Alexandrovna Tsvetkova, Zhemal Zarifovna Rakhmanova, Andrei Vadimovich Kozlov, Alexei Borisovich Chukhlovin, Ilya Viktorovich Kazantsev, Maria Arkadievna Estrina, Oleg Valerievich Goloshchapov, Sergei Nikolaevich Bondarenko, Ivan Sergeevich Moiseev, Alexander Dmitrievich Kulagin, Ludmila Stepanovna Zubarovskaya

Cite

APA

Borovkova, A. S., Paina, O. V., Semenova, E. V., Bykova, T. A., Osipova, A. A., Slesarchuk, O. A., Kozhokar, P. V., Tsvetkova, L. A., Rakhmanova, Z. Z., Kozlov, A. V., Chukhlovin, A. B., Kazantsev, I. V., Estrina, M. A., Goloshchapov, O. V., Bondarenko, S. N., Moiseev, I. S., Kulagin, A. D., & Zubarovskaya, L. S. (2024). Post‐transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia. Clinical Transplantation. https://doi.org/10.1111/ctr.15181

Vancouver

Borovkova AS, Paina OV, Semenova EV, Bykova TA, Osipova AA, Slesarchuk OA, et al. Post‐transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia. Clinical Transplantation. 2024. doi:10.1111/ctr.15181

BibTeX
@article{Borovkova2024,
  author = {Borovkova, Anastasya Svyatoslavovna and Paina, Olesya Vladimirovna and Semenova, Elena Vladimirovna and Bykova, Tatiana Alexandrovna and Osipova, Anna Alekseevna and Slesarchuk, Olga Alexandrovna and Kozhokar, Polina Valerievna and Tsvetkova, Lubov Alexandrovna and Rakhmanova, Zhemal Zarifovna and Kozlov, Andrei Vadimovich and Chukhlovin, Alexei Borisovich and Kazantsev, Ilya Viktorovich and Estrina, Maria Arkadievna and Goloshchapov, Oleg Valerievich and Bondarenko, Sergei Nikolaevich and Moiseev, Ivan Sergeevich and Kulagin, Alexander Dmitrievich and Zubarovskaya, Ludmila Stepanovna},
  title = {Post‐transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15181}
}
Start for free →